IP Library › Granted Patent US 12,570,997
Granted Patent B2
US 12,570,997 · App. 17/602,343 · Granted Mar 10, 2026

Factor H vectors and uses thereof

Inventors: Guangping Gao (Worcester, MA); Jun Xie (Worcester, MA)
Assignee: University of Massachusetts
C12N15/86C07K14/4705C07K14/472C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,570,997
App. No.
17/602,343
Granted
Mar 10, 2026
Kind
B2
Abstract

Aspects of the disclosure relate to compositions and methods for expressing a Factor H protein (or a variant thereof) in a cell or subject. In some embodiments, the disclosure provides isolated nucleic acids and rAAVs comprising a transgene encoding a Factor H protein variant and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with Factor H deficiency.

Claims (18)

1 . An isolated nucleic acid encoding the amino acid sequence set forth in SEQ ID NO: 3, wherein the nucleic acid sequence is operably linked to SEQ ID NO: 19 and SEQ ID NO: 14, and further comprises a promoter comprising the nucleic acid sequence set forth in SEQ ID NOs: 10 and 12.

2 . The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises the sequence set forth in SEQ ID NO: 4.

3 . The isolated nucleic acid of claim 1 , wherein the promoter further comprises an enhancer sequence, wherein the enhancer sequence comprises the sequence set forth in SEQ ID NO: 9 or 10.

4 . The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid comprises one or more introns.

5 . The isolated nucleic acid of claim 4 , wherein at least one intron is positioned between the promoter and the nucleic acid sequence.

6 . The isolated nucleic acid of claim 4 , wherein at least one intron comprises the sequence set forth in any one of SEQ ID NOs: 13-15.

7 . The isolated nucleic acid of claim 1 further comprising a 3′ untranslated region (3′UTR).

8 . The isolated nucleic acid of claim 7 , wherein the 3′UTR comprises the sequence set forth in SEQ ID NO: 17 or 18.

9 . A vector comprising the isolated nucleic acid of claim 1 .

10 . The vector of claim 9 , wherein the vector is a plasmid or a viral vector.

11 . The vector of claim 10 , wherein the viral vector is an adenoviral vector, adeno-associated virus vector, a lentiviral vector, a retroviral vector, or a Baculovirus vector.

12 . A host cell comprising the vector of claim 9 .

13 . The host cell of claim 12 , wherein the host cell is a mammalian cell, yeast cell, bacterial cell, or insect cell.

14 . A recombinant adeno-associated virus (rAAV) comprising:

(i) the isolated nucleic acid of claim 1 ; and

(ii) an adeno-associated virus (AAV) capsid protein.

15 . The rAAV of claim 14 , wherein the capsid protein has a tropism for muscle tissue or ocular tissue.

16 . The rAAV of claim 14 , wherein the capsid protein is of a serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or a variant thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2022
From: GAO, GUANGPING; XIE, JUN
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 059184/0166 →
Continuity (2)
Provisional Application 62831870 · Apr 10, 2019
Related Publication 20220162641A1 · May 26, 2022
References Cited (27)
US 10988519B2 · Song et al. · 2021 [cited by examiner]
US 20180214576A1 · Fitzgerald et al. · 2018 [cited by examiner]
US 20180230488A1 · Hinderer et al. · 2018 [cited by applicant]
CN 108291216A · 2018 [cited by applicant]
JP 2016531910A · 2016 [cited by applicant]
JP 2018527941A · 2018 [cited by applicant]
WO WO2011133890A1 · 2011 [cited by applicant]
WO WO2015023972A1 · 2015 [cited by applicant]
WO WO2017053732A2 · 2017 [cited by applicant]
WO WO2018106956A2 · 2018 [cited by applicant]
Davos et al., (Proteins: Structure, Function and Genetics, 2000, vol. 41: 98-107. [cited by examiner]
Wristlock et al., (Quarterly Reviews of Biophysics 2003, vol. 36 (3): 307-340. [cited by examiner]
Kwiatkowski et al., (Biochemistry 38:11643-11650, 1999. [cited by examiner]
Kisselev L., (Structure, 2002, vol. 10: 8-9. [cited by examiner]
PCT/US2020/027452, Jul. 7, 2020, Invitation to Pay Additional Fees. [cited by applicant]
PCT/US2020/027452, Sep. 30, 2020, International Search Report and Written Opinion. [cited by applicant]
PCT/US2020/027452, Oct. 21, 2021, International Preliminary Report on Patentability. [cited by applicant]
Lu et al., Advances in Transfer Methods For Gene Therapy. Foreign Medical Sciences (Section of Medgeography). Feb. 12, 1996. Issue 01. pp. 1-6. [cited by applicant]
Extended European Search Report for Application No. 20788329.9, mailed Nov. 21, 2022. [cited by applicant]
Borel et al., Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther. Apr. 2014;22(4):692-701. doi: 10.1038/mt.2013.285. Epub Dec. 19, 2013. [cited by applicant]
Qiao et al., Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther. Apr. 2011;18(4):403-10. doi: 10.1038/gt.2010.157. Epub Dec. 9, 201… [cited by applicant]
Xiao et al., Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. JCI Insight. Jul. 11, 2019; 4(13): e99052. Published on… [cited by applicant]
Invitation to Pay Additional Fees for Application No. PCT/US2020/027452, mailed Jul. 7, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/027452, mailed Sep. 30, 2020. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2020/027452, mailed Oct. 21, 2021. [cited by applicant]
Gu et al., Transduction of Adeno-Associated Virus Vectors Targeting Hair Cells and Supporting Cells in the Neonatal Mouse Cochlea. Front Cell Neurosci. Jan. 24, 2019:13:8. doi: 10.3389/fncel.2019.00008. eCollection 2019. [cited by applicant]
EP 20788329.9, Nov. 21, 2022, Extended European Search Report. [cited by applicant]